Mainz Biomed B.V. (MYNZ) 6-K 6 Sep 22 Management’s Discussion and Analysis of Financial Condition and Results of Operations Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	MAINZ BIOMED N.V.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001874252
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity File Number	001-41010

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash	$ 26,006,609	$ 8,727,542
Trade and other receivables, net	332,918	111,842
Inventories	36,694
Prepaid expenses	422,090	769,825
Total Current Assets	26,798,311	9,609,209
Property and equipment	267,940	37,884
Right-of-use asset	537,569	393,702
Other asset	11,532
Total assets	27,615,352	10,040,795
Current Liabilities
Accounts payable and accrued liabilities	1,205,788	784,786
Accrued payroll	44,447	233,710
Accounts payable - related party	104,840	84,750
Convertible debt - related party	72,930	77,887
Loans payable		22,754
Loans payable - related party		92,792
Silent partnership	732,339
Silent partnership - related party	198,549
Lease liabilities	114,669	55,076
Total current liabilities	2,473,562	1,351,755
Silent partnerships	648,207	1,463,981
Silent partnerships - related party	246,625	476,138
Lease liabilities	475,148	387,766
Total Liabilities	3,843,542	3,679,640
Shareholder’s equity
Share capital	163,332	141,075
Share premium	38,256,659	13,126,493
Reserve	14,514,102	9,736,066
Accumulated deficit	(29,247,405)	(16,644,958)
Accumulated other comprehensive income	85,122	2,479
Total shareholders’ equity	23,771,810	6,361,155
Total liabilities and shareholders’ equity	$ 27,615,352	$ 10,040,795

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Profit and Loss and Comprehensive Loss (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Profit or loss [abstract]
Revenue	$ 239,805	$ 417,311
Cost of revenue	119,005	64,772
Gross profit	120,800	352,539
Operating expenses
General and administrative	9,268,054	250,692
Sales and marketing	2,520,496	150,335
Research and development	911,716	206,146
Total operating expenses	12,700,266	607,173
Loss from operations	(12,579,466)	(254,634)
Other income (expense)
Accretion expense	(40,697)	(95,687)
Government grant – research and development	69,109	143,712
Government grant – below market financing		1,897
Interest expense	(75,216)	(73,364)
Other income	23,823	16,355
Total other expense	(22,981)	(7,087)
Loss before income tax	(12,602,447)	(261,721)
Income taxes provision
Net loss	(12,602,447)	(261,721)
Foreign currency translation gain	82,643	82,963
Comprehensive loss	$ (12,519,804)	$ (178,758)
Basic and dilutive loss per ordinary share (in Dollars per share)	$ (0.91)	$ (0.05)
Weighted average number of ordinary shares outstanding (in Shares)	13,821,914	5,607,243

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Profit and Loss and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Profit or loss [abstract]
Basic and dilutive loss per ordinary share	$ (0.91)	$ (0.05)

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($)	Share Capital	Share Premium	Reserve	Accumulated Deficit	Accumulated Other comprehensive Income (loss)	Total
Balance at Dec. 31, 2020	$ 64,265	$ 41,846	$ 2,309,684	$ (4,954,860)	$ (202,490)	$ (2,741,555)
Balance (in Shares) at Dec. 31, 2020	5,607,243
Issuance of ordinary shares for conversion of debt	$ 4,784	3,115	500,338			508,237
Issuance of ordinary shares for conversion of debt (in Shares)	392,757
Net loss				(261,721)		(261,721)
Foreign currency translation					82,963	82,963
Balance at Jun. 30, 2021	$ 69,049	44,961	2,810,022	(5,216,581)	(119,527)	(2,412,076)
Balance (in Shares) at Jun. 30, 2021	6,000,000
Balance at Dec. 31, 2021	$ 141,075	13,126,493	9,736,066	(16,644,958)	2,479	6,361,155
Balance (in Shares) at Dec. 31, 2021	12,010,001
Sale of ordinary shares	$ 15,525	23,850,364				23,865,889
Sale of ordinary shares (in Shares)	1,725,000
Issuance of ordinary shares for exercise of warrants	$ 6,210	492,704	(116,414)			382,500
Issuance of ordinary shares for exercise of warrants (in Shares)	689,973
Share based expense	$ 522	787,098				787,620
Share based expense (in Shares)	58,000
Stock option expense			4,894,450			4,894,450
Net loss				(12,602,447)		(12,602,447)
Foreign currency translation					82,643	82,643
Balance at Jun. 30, 2022	$ 163,332	$ 38,256,659	$ 14,514,102	$ (29,247,405)	$ 85,122	$ 23,771,810
Balance (in Shares) at Jun. 30, 2022	14,482,974

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows From Operating Activities
Net loss	$ (12,602,447)	$ (261,721)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	5,682,070
Depreciation and amortization	62,369	34,835
Bad debt expense	470
Accretion expense	40,697	95,687
Changes in operating assets and liabilities:
Trade and other receivables	(47,371)	(32,325)
Inventory	(38,269)
Prepaid expenses and other assets	332,078	7,143
Accounts payable and accrued liabilities	113,499	23,851
Net cash used in operating activities	(6,456,904)	(132,530)
Cash Flows From Investing Activities
Purchase of property and equipment	(252,446)	(4,580)
Net cash used in investing activities	(252,446)	(4,580)
Cash Flows From Financing Activities
Sale of ordinary shares and warrants	23,865,890
Warrant exercise proceeds	382,500
Proceeds from silent partnerships		241,040
Repayment of loans payable	(111,049)
Repayment of lease obligations	(45,690)	(24,011)
Net cash provided by financing activities	24,091,651	217,029
Effect of changes in exchange rates	(103,234)	(7,322)
Net change in cash	17,279,067	72,597
Cash at beginning of period	8,727,542	122,568
Cash at end of period	26,006,609	195,165
Non-Cash Investing And Financing Activities
Right of use asset additions	235,221	12,346
Issuance of common stock for conversion of debt and accrued interest		508,237
Supplemental Cash Flow Disclosures:
Interest paid	57,677	23,959
Tax paid

Nature of Operations and Going

Nature of Operations and Going Concern	6 Months Ended
	Jun. 30, 2022
Nature of Operations and Going Concern [Abstract]
NATURE OF OPERATIONS AND GOING CONCERN	1. NATURE OF OPERATIONS AND GOING CONCERN Mainz Biomed N.V. (the “Company”) is domiciled in the Netherlands. The Company’s registered office is at Keizersgracht 391A, EJ Amsterdam. The Company was formed to acquire the business of Mainz Biomed Germany GmbH (f/k/a PharmGenomics GmbH (“PharmaGenomics”, “PG”)). In September 2021, the Company completed such acquisition. We develop in-vitro diagnostic (“IVD”) tests for clinical diagnostics in the area of human genetics, focusing in the areas of personalized medicine, led by our flagship ColoAlert™ product in European markets. We additionally operate a clinical diagnostic laboratory. We develop and distribute our IVD kits to third-party laboratories and through our on-line store. Throughout these consolidated financial statements, Mainz Biomed N.V. and its wholly owned subsidiaries, Mainz Biomed USA, Inc. and Mainz Biomed GmbH (f/k/a PharmGenomics GmbH), are referred to, collectively and individually as “Mainz”, “Mainz Biomed”, or the “Company”. Share Exchange On August 3, 2021, the Company entered into a contribution agreement (the “Contribution Agreement”) between Mainz Biomed B.V. (“Mainz”), which was a private company with limited liability under Dutch law incorporated for the purpose of acquiring PharmGenomics. Under the Contribution Agreement, 100% of the shares of PharmGenomics were acquired in exchange for 6,000,000 shares of the Company. Upon the closing of the Contribution Agreement, PharmGenomics became a wholly owned subsidiary of the Company and the former shareholders of PharmGenomics held approximately 62% of the outstanding shares of the Company prior to the Company’s initial public offering. On September 20, 2021 PharmGenomics and the Company closed the Contribution Agreement. In November 2021, the Company completed its initial public offering of its ordinary shares on the Nasdaq Capital Market, selling 2,300,000 shares at $5.00 per share. Upon its IPO, Mainz Biomed B.V. became Mainz Biomed N.V. Going Concern The Company has recurring losses, accumulated deficit totaling $29,247,405 and negative cash flows used in operating activities of $6,456,904 as of and for the six months ended June 30, 2022. The Company has sufficient cash on hand, including from the ordinary share offering completed in January 2022, to cover its current liabilities and the estimated cash to be used in operations based for the next twelve months. As a result of the actions noted above, management believes that it will have sufficient working capital to meet its planned operating cash flow requirements. These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. These financial statements do not reflect the adjustments to the carrying values of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used, that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. COVID-19 Impact On March 11, 2020, the outbreak of the novel strain of coronavirus specifically identified as “COVID-19” was declared a pandemic by the World Health Organization. The outbreak has resulted in governments worldwide enacting emergency measures to combat the spread of the virus which in turn have caused material disruption to business globally. Global equity markets have experienced significant volatility and weakness. Governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions and the severity and frequency of new strains of the coronavirus. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company in future periods.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Disclosure of Basis of Presentation [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION Basis of Presentation and Statement of Compliance These condensed interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standards (“IAS”) 34, “Interim Financial Reporting” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and International Financial Reporting Interpretations Committee (“IFRIC”). These condensed interim financial statements do not include all of the information required of a full set of annual financial statements and are intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that these condensed interim financial statements be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2021 and notes thereto contained in the Company’s Form 20-F. These condensed interim financial statements have been prepared on a historical cost basis, modified where applicable. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting except for cash flow information. The condensed interim financial statements were authorized for issuance by the Audit Committee of the Board of Directors on September 1, 2022. New Accounting Standards Standards, interpretations and amendments to standards and interpretations in the reporting period not yet effective and not yet applied ● In February 2021, the International Accounting Standards Board issued narrow-scope amendments to IAS 1, Presentation of Financial Statements Making Materiality Judgements , Accounting Policies, Changes in Accounting Estimates and Errors ● In May 2021, the International Accounting Standards Board issued targeted amendments to IAS 12, Income Taxes

Accounting Policies, Estimates

Accounting Policies, Estimates and Significant Management Judgments	6 Months Ended
	Jun. 30, 2022
Significant accounting policies [Abstract]
ACCOUNTING POLICIES, ESTIMATES AND SIGNIFICANT MANAGEMENT JUDGMENTS	3. ACCOUNTING POLICIES, ESTIMATES AND SIGNIFICANT MANAGEMENT JUDGMENTS Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on a weighted average cost and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation. Critical Accounting Estimates and Significant Management Judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Useful lives of property and equipment Estimates of the useful lives of property and equipment are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment would increase the recorded expenses and decrease the non-current assets. Provision for expected credit losses on trade receivables The provision for expected credit losses on trade receivables are estimated based on historical information, customer concentrations, customer solvency, current economic and geographical trends, and changes in customer payment terms and practices. The Company will calibrate its provision matrix to adjust the historical credit loss experience with forward-looking information. The assessment of the correlation between historical observed default rates, forecast economic conditions and expected credit losses is a significant estimate. The amount of expected credit losses is sensitive to changes in circumstances and of forecast economic conditions. The Company’s historical credit loss experience and forecast of economic conditions may also not be representative of customer’s actual default in the future. Estimating the incremental borrowing rate on leases The Company cannot readily determine the interest rate implicit in leases where it is the lessee. As such, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of comparable value to the right-of-use asset in a similar economic environment. IBR therefore reflects what the Company “would have to pay”, which requires estimation when no observable rates are available or where the applicable rates need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates. Estimating the fair value of share-based payment transactions The Company utilizes a Black-Scholes model, or where appropriate, a Monte-Carlo Simulation to estimate the fair value of its share-based payments. In applying these models, management must estimate the expected future volatility of the Company’s estimated share price, and makes such assumptions based on a proxy of publicly-listed entities under an expectation that historical volatility is representative of the expected future volatility. Additionally, estimates have been made by management, in respect of the performance warrants, regarding the length of the vesting period as well as the number of performance warrants that are likely to vest. Estimating the fair value of financial instruments When the Company recognizes a financial instrument, where there is no active market for such instrument, the Company utilizes alternative valuation methods. The Company utilizes inputs from observable markets to the extent that an appropriate market can be identified, but when there is a lack of such a market, the Company applies judgment to determine a fair value. Such judgments require those such as risk and volatility, of which changes in such assumptions may impact the fair value of the financial instrument. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include: ● The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty; ● The determination of the lease term of contracts with renewal and termination options; ● Determination of the extent to which it is probable that future taxable income will be available to allow all or part of the temporary differences and net operating losses to be utilized; ● Whether there are indicators of impairment of the Company’s long-lived assets; ● That Mainz Biomed N.V. did not constitute a business at the time of the contribution agreement; and ● Development costs do not meet the conditions for capitalization in accordance with IAS 38 and therefore all research and development costs have been expensed as incurred.

Trade and Other Receivables

Trade and Other Receivables	6 Months Ended
	Jun. 30, 2022
Trade and other receivables [Abstract]
TRADE AND OTHER RECEIVABLES	4. TRADE AND OTHER RECEIVABLES June 30, December 31, 2022 2021 Accounts receivable $ 59,768 $ 17,995 Less: allowance for doubtful accounts (734 ) (796 ) Accounts receivable, net 59,034 17,199 VAT receivable 271,694 94,085 Other 2,190 558 $ 332,918 $ 111,842

Prepaid and Other Current Asset

Prepaid and Other Current Assets	6 Months Ended
	Jun. 30, 2022
Disclosure of Prepaid and Other Current Assets [Abstract]
PREPAID AND OTHER CURRENT ASSETS	5. PREPAID AND OTHER CURRENT ASSETS June 30, December 31, 2022 2021 Prepaid insurance $ 361,185 $ 743,750 Other prepaid expense 31,665 12,590 Security deposit 29,240 13,485 $ 422,090 $ 769,825

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Disclosure Of Leases Text Block Abstract
LEASES	6. LEASES Right-of-Use Assets The Company’s leases certain assets under lease agreements. Office Laboratory Equipment Equipment Vehicles Office lease Total Cost Balance at January 1, 2021 $ 31,584 $ 11,234 $ - $ 527,285 $ 570,103 Additions 20,233 12,121 - - 32,354 Effects of currency translation (3,063 ) (1,279 ) - (38,142 ) (42,484 ) Balance at December 31, 2021 $ 48,754 $ 22,076 $ - $ 489,143 $ 559,973 Additions 18,610 117,011 58,834 40,768 235,223 Effects of currency translation (4,593 ) (6,549 ) (2,422 ) (40,067 ) (53,631 ) Balance at June 30, 2022 $ 62,771 $ 132,538 $ 56,412 $ 489,844 $ 741,565 Accumulated amortization Balance at January 1, 2021 $ 3,983 $ 2,340 $ - $ 107,245 $ 113,568 Amortization 6,135 5,487 - 51,734 63,356 Effects of currency translation (524 ) (380 ) - (9,749 ) (10,653 ) Balance at December 31, 2021 $ 9,594 $ 7,447 $ - $ 149,230 $ 166,271 Amortization 5,788 14,143 7,080 25,943 52,954 Effects of currency translation (991 ) (1,166 ) (291 ) (12,781 ) (15,229 ) Balance at June 30, 2022 $ 14,391 $ 20,424 $ 6,789 $ 162,392 $ 203,996 As of June 30, 2022, management assessed that there were no events or changes in circumstances that would require impairment testing. The carrying amount of the right-of-use assets is amortized on a straight-line basis over the life of the leases, which at June 30, 2022, had an average expected life of 5 years. Lease Liabilities The Company’s lease liabilities consist of office and laboratory equipment and office space. The present value of future lease payments were measured using an incremental borrowing rate of 10% per annum as of January 1, 2021 and January 1, 2022. Total Balance as of January 1, 2021 $ 495,051 Additions 32,955 Interest expenses 47,102 Lease payments (97,429 ) Effects of currency translation (34,835 ) As of December 31, 2021 $ 442,844 Additions 235,221 Interest expenses 25,338 Lease payments (71,029 ) Effects of currency translation (42,557 ) As of June 30, 2022 $ 589,817 Lease liabilities June 30, December 31, Current portion $ 114,669 $ 55,076 Long-term portion 475,148 387,766 Total lease liabilities $ 589,817 $ 442,842 At June 30, 2022, the Company is committed to minimum lease payments as follows: Maturity analysis June 30, Less than one year $ 77,108 One to two years 154,216 Two to three years 151,782 Three to four years 95,580 Four to five years 82,443 More than five years 133,238 Total undiscounted lease liabilities $ 694,367 Amount representing implicit interest (104,550 ) Lease obligations $ 589,817

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Accounts Payable And Accrued Expenses Abstract
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	7. ACCOUNTS PAYABLE AND ACCRUED EXPENSES June 30, December 31, 2022 2021 Accounts payable $ 503,181 $ 747,768 Accrued liabilities 51,633 26,989 Payroll liabilities 50,974 6,812 Bonus accrual 600,000 - VAT payable - 3,217 $ 1,205,788 $ 784,786

Convertible Debt _ Related Part

Convertible Debt – Related Party	6 Months Ended
	Jun. 30, 2022
Disclosure Of Convertible Debt Explanatory Abstract
CONVERTIBLE DEBT – RELATED PARTY	8. CONVERTIBLE DEBT – RELATED PARTY During the years ended December 31, 2019 and 2020, the Company entered into loan agreements with related parties totaling EUR 417,133 (approximately $467,154) (the “2019 and 2020 Convertible Loans”). The 2019 and 2020 Convertible Loans bear interest at 3.5% and have a maturity date of September 30, 2022. While the 2019 and 2020 Convertible Loans are outstanding, the lenders are entitled to 0.5% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. As the Company incurred losses during 2021, 2020 and 2019, no expense has been recorded in any period for profit sharing. At maturity, the 2019 and 2020 Convertible Loans are convertible into ordinary shares of the Company at EUR 1 per share. The 2019 and 2020 Convertible Loans were determined to be a financial instrument comprising an equity classified conversion feature with a host debt component. On initial recognition, the Company used the residual value method to allocate the principal amount of the 2019 and 2020 Convertible Loans between the two components. The host debt component was valued first, based on similar debt securities without an embedded conversion feature and the residual was allocated to the equity-classified conversion feature. The Company recognized debt discounts totaling EUR 13,064 on issuance of the 2019 and 2020 Convertible Loans. In November 2017, the Company entered into loan agreements with two shareholders of the Company for loans totaling EUR 80,278 (approximately $92,007) (the “2017 Convertible Loans”). The loans are convertible at the option of the lender to shares totaling 4.25% of the Company’s common shares outstanding at the time of conversion. The loans are non-interest bearing, are unsecured and are due on demand. During the year ended December 31, 2019, principal in the amount of EUR 5,000 ($5,597) was exchanged for the 2019 and 2020 Convertible Loans and EUR 5,000 ($5,597) was extinguished as the lender elected to offset the debt amount against amounts in trade receivables due to the Company. During the year ended December 31, 2021, the loan amount of EUR 417,272 ($508,237) were converted into 392,757 shares of share capital and the Company received cash of EUR 6,485 ($7,673) to issue shares. A continuity of the Company’s Convertible Debt – Related Party is as follows: 2019 and 2020 2017 Total Balance, January 1, 2021 $ 447,181 $ 86,189 $ 533,370 Accretion 60,136 - 60,136 Conversion (471,528 ) (36,709 ) (508,237 ) Effects of currency translation (3,568 ) (3,814 ) (7,382 ) Balance, December 31, 2021 $ 32,221 $ 45,666 $ 77,887 Accretion 1,205 - 1,205 Effects of currency translation (2,578 ) (3,584 ) (6,162 ) Balance, June 30, 2022 $ 30,848 $ 42,082 $ 72,930

Loans Payable

Loans Payable	6 Months Ended
	Jun. 30, 2022
Loans Payable [Abstract]
LOANS PAYABLE	9. LOANS PAYABLE During the year ended December 31, 2020, the Company entered into a loan agreement for the principal amount of EUR 20,000 (approximately $22,828) (the “0.1% Loan). The 0.1% Loan bears interest at 0.1% per month and is due on demand and is secured against the Company’s trade receivables. Between the years of 2011 to 2013, the Company received loans from related parties totaling EUR 35,000 (approximately $40,144) (the “Related Party 6% Loans”). The Loans have a stated interest rate of at 6.0%. EUR 10,000 (approximately $11,461) of the loans matured on July 31, 2020 and EUR 25,000 (approximately $28,653) of the loan matured on December 31, 2021. As the Related Party 6% Loans were received at below market interest rates, the initial fair value of the 3% Loan was determined to be EUR 21,936 (approximately $25,140), determined using an estimated effective interest rate of 11.5%. In 2017, the Company obtained a line of credit of up to EUR 200,000 (approximately $229,224) (the “LOC”). The LOC accrues interest of 4% on amounts drawn, and a 0.5% fee if no amounts are drawn. The LOC was fully repaid in early 2022. During the six months ended June 30, 2022, loans payable was fully paid off. A continuity of the Company’s loans payable is as follows: 0.1% Loan Related party Related party Total Balance, January 1, 2021 $ 24,528 $ 41,326 $ 66,979 $ 132,833 Issued during the year - - 2,305 2,305 Extinguished during the year - - (11,832 ) (11,832 ) Accretion - 1,542 - 1,542 Effects of currency translation (1,774 ) (3,049 ) (4,479 ) (9,302 ) Balance, December 31, 2021 $ 22,754 $ 39,819 $ 52,973 $ 115,546 Extinguished during the year (21,868 ) (38,269 ) (52,777 ) (112,914 ) Effects of currency translation (886 ) (1,550 ) (196 ) (2,632 ) Balance, June 30, 2022 $ - $ - $ - $ -

Silent Partnerships

Silent Partnerships	6 Months Ended
	Jun. 30, 2022
Silent Partnerships Abstract
SILENT PARTNERSHIPS	10. SILENT PARTNERSHIPS During the year ended December 31, 2020, the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR 299,400 (approximately $341,740) (the “3% SPAs”). The Company is to repay the amount by December 31, 2025. The Company must pay a minimum of 3% interest per annum on the loans. The lender is entitled to 3% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. Upon the amounts coming due, the lender of the 3% SPAs have the option to demand an additional payment equal to 15% of the contribution as a final remuneration (the “Final Renumeration”). The Final Remuneration is considered to be the cost of issuing debt. The 3% SPAs were received at below market interest rates as part of a government program for COVID-19 relief. The initial fair value of the 3% SPAs was determined to be EUR 218,120 (approximately $248,966), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3% SPAs of EUR 81,280 ($92,774) has been recognized as government grant income during the period. During the year ended December 31, 2021 the Company received the remaining EUR 200,000 ($236,640). The initial fair value of the 3.0% SPAs received was determined to be EUR 230,000 (approximately $272,136), determined using an estimated effective interest rate of 11.5%. The initial fair value of the 3.0% SPAs received in 2021 was determined to be EUR 156,549 (approximately $185,229), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3.0% SPAs received in 2021 of EUR 43,451 (approximately $51,410) has been recognized as government grant income during the period. During the year ended December 31, 2020, the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR 50,000 (approximately $57,071) (the “3.5% SPAs”). The Company is to repay the amount by June 30, 2025. The Company must pay a minimum of 3.5% interest per annum on the loans. The lender is entitled to 0.5% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the ender does not partake in the Company’s losses. The 3.5% SPAs are convertible to common shares of the Company at EUR 1 per share in the event that the Company is involved in any of the following transactions: capital increases, a share or asset deal or a public offering. Pursuant to the silent partnership agreement, the Company notified the holder, at which point the holder declined the opportunity to convert their loan into common shares. The 3.5% SPAs were determined to be a financial instrument comprising an equity classified conversion feature with a host debt component. On initial recognition, the Company used the residual value method to allocate the principal amount of the 3.5% SPAs between the two components. The host debt component was valued first, based on similar debt securities without an embedded conversion feature and the residual was allocated to the equity-classified conversion feature. Between the years of 2013 to 2016, the Company entered into silent partnership agreements for loans totaling EUR 798,694 (approximately $915,383) (the “8.5% SPAs”). Under the 8.5% SPAs, the Company is to repay EUR 398,634 (approximately $408,496) of the loans by June 30, 2023 and EUR 400,000 (approximately $409,859) of the loans matures on December 31, 2025. The Company must pay a minimum of 8.5% interest per annum on the loans. The lenders are entitled to 1.66% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. At maturity, the lenders of the 8.5% SPAs have the option to demand an additional payment equal to 30% of the principal of the loans as a Final Remuneration. The Final Remuneration is considered to be cost of issuing the debt and as such, the initial fair value of the 8.5% SPAs was determined to be EUR 772,568 (approximately $85,440), determined using an estimated effective interest rate of 11.5%. Under the agreements, the lenders also agreed to invest in the Company and contributed EUR 676,366 (approximately $775,183) to acquire 27,752 shares of the Company between the years of 2013 and 2016. During the year ended December 31, 2020, EUR 80,000 (approximately $99,527) of the 8.5% SPAs was extinguished as the lender, who is also a customer of the Company, elected to offset the debt amount against amounts in trade receivables due to the Company. The debtor did not demand the Final Remuneration and the Company recognized a gain on the extinguishment of $8,214. In 2010, the Company entered into a silent partnership agreement whereby the lender agreed to lend the Company EUR 300,000 (approximately $343,830) (the “8% SPA”). The Company must repay the loan by January 31, 2023. The Company must pay a minimum of 8% interest per annum on the loan. The lender is entitled to 1.95% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. At maturity, the lender of the 8% SPA has the option to demand an additional payment of up to 30% of the principal of the loan as a Final Remuneration. The Final Remuneration is considered to be cost of issuing the debt and as such, the initial fair value of the 8% SPA was determined to be EUR 289,900 (approximately $332,254), determined using an estimated effective interest rate of 11.5%. A continuity of the Company’s silent partnerships is as follows: 3% SPAs 3.5% SPAs 8.5% SPAs 8% SPAs Total Balance, January 1, 2021 $ 288,558 $ 43,313 $ 1,030,167 $ 456,212 $ 1,818,250 Issued during the year 236,636 - - - 236,636 Discount - - (51,410 ) - (51,410 ) Accretion 34,970 3,214 30,018 10,093 78,295 Effects of currency translation (31,315 ) (3,256 ) (73,694 ) (33,387 ) (141,652 ) Balance, December 31, 2021 $ 528,849 $ 43,271 $ 935,081 $ 432,918 $ 1,940,119 Accretion 19,166 1,557 14,066 4,704 39,493 Effects of currency translation (42,294 ) (3,460 ) (73,967 ) (34,171 ) (153,892 ) Balance, June 30, 2022 $ 505,721 $ 41,368 $ 875,180 $ 403,451 $ 1,825,720

Equity

Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
EQUITY	11. EQUITY Ordinary shares The Company has 45 million ordinary shares authorized. Holders of ordinary shares are entitled to dividends as declared from time to time and are entitled to one vote per share at general meetings of the Company. The par value of share capital is EUR 0.01 per share. During the six months ended June 30, 2022, the Company issued ordinary shares as follows: ● 1,725,000 ordinary shares issued for gross proceeds of approximately $25.9 million (proceeds net of offering expenses was $23.9 million); ● 689,973 ordinary shares issued for exercise of warrants, including cashless exercises (proceeds from cash exercises of warrants was $382,500); and ● 58,000 ordinary shares issued for services valued at $787,620 Warrants During the year ended December 31, 2021, in conjunction with private sales of ordinary shares, the Company issued 3,755,000 warrants and issued 140,000 underwriter warrants with its IPO, cumulatively valued at $754,286, which was recorded to Reserve in the Statement of Financial Position. The warrants were valued using the Black-Scholes pricing model. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. For the year ended December 31 2021, the estimated fair values of the warrants measured are as follows: December 31, 2021 Stock price at time of issuance $ 0.283 - 1.602 Exercise price $ 3.00 Expected term 2 - 5 years Expected average volatility 75 - 95 % Expected dividend yield 0 Risk-free interest rate 0.16 - 1.08 % A summary of activity during the six months ended June 30, 2022 is as follows: Warrants Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2021 3,895,000 $ 3.08 1.60 Grants - - - Exercised (507,500 ) 3.00 1.46 Expired - - - Balance as of June 30, 2022 3,387,500 $ 3.08 1.08 Stock options During 2021, we adopted our 2021 Omnibus Incentive Plan, and on June 28, 2022 we adopted our 2022 Omnibus Incentive Plan (the “Plans”). Under the Plans, we are authorized to issue equity incentives in the form of incentive stock options, non-statutory stock options, restricted shares, restricted share units, share appreciation rights, performance units or performance shares under separate award agreements. Under the Plans, the aggregate number of shares underlying awards that we could issue cannot exceed 2,800,000 ordinary shares. During the year ended December 31, 2021, the Company granted 1,504,650 stock options valued at $13,968,627. Stock options with time-based vesting were valued using the Black-Scholes pricing model, while stock options with market-based vesting were valued using the Monte Carlo simulation. During the year ended December 31, 2021, the Company recorded share-based compensation of $6,430,158 and the unamortized expense of $7,538,469 as of December 31, 2021. Forfeitures are estimated at the time of grant and adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the six months ended June 30, 2022, the Company granted 487,000 stock options valued at $4,336,798. Stock options with time-based vesting were valued using the Black-Scholes pricing model. During the six months ended June 30, 2022, the Company recorded share-based compensation of $4,894,450 and had unamortized expense of $6,952,548 as of June 30, 2022. Forfeitures are estimated at the time of grant and adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the six months ended June 30, 2022, the estimated fair values of the stock options are as follows: June 30, 2022 Exercise price $ 8.91 - 20.87 Expected term 5.55 - 6.75 years Expected average volatility 73% - 79 % Expected dividend yield - Risk-free interest rate 1.26% - 3.38 % A summary of activity during the six months ended June 30, 2022 follows: Stock Options Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2021 1,504,650 $ 5.10 9.85 Grants 487,000 13.16 10.00 Exercised - - - Expiry - - - Balance as of June 30, 2022 1,991,650 $ 7.07 9.46 Exercisable as of June 30, 2022 933,040 $ 5.14 9.36

Cost of Revenue

Cost of Revenue	6 Months Ended
	Jun. 30, 2022
Cost of Revenue [Abstract]
COST OF REVENUE	12. COST OF REVENUE For the six-month periods ended June 30, 2022 and 2021, cost of revenue consisted of test kit materials.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	13. RELATED PARTY TRANSACTIONS Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company’s Board, its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Chief Scientific Officer. The remuneration of directors and key management personnel during the six months ended June 30, 2022 and 2021 was as follows: Six months ended June 30, 2022 2021 Salaries and benefits $ 1,264,187 $ 109,733 Remuneration paid to related parties other than key personnel during the six months ended June 30, 2022 and 2021 was as follows: Six months ended June 30, 2022 2021 Salaries and benefits $ 61,116 $ 943 During the six months ended June 30, 2022 and 2021, the Company incurred interest expense of $16,838 and $24,983 on balances owing to related parties, respectively. During the six months ended June 30, 2022 and 2021, the Company incurred accretion expense of $7,885 and $9,908 on balances owing to related parties, respectively. As at June 30, 2022, EUR 30,000 (approximately $31,452) with a carrying value of $30,848 (2021 – $33,767) of the 2019 and 2020 Convertible Loans were owing to the Chief Scientific Officer of the Company and a major shareholder of the Company, respectively. The amounts are due on September 30, 2022. As at June 30, 2022, EUR 350,000 (approximately $366,940) (2021 – EUR 350,000) with a carrying value of $445,174 (2021 – $498,972) of the 8.5% SPAs were owing to major shareholders of the Company. EUR 150,000 of the loan is due on June 30, 2023 and EUR 200,000 of the loan is due on December 31, 2025. During the six months ended June 30, 2022 and 2021, we recorded expenses of $126,173 and $0, respectively, for the cost of royalties and other associated costs owed to ColoAlert AS, the company from which we exclusively license the ColoAlert product. Our Board Chairman is also a significant equity holder of ColoAlert AS. During the six months ended June 30, 2022 and 2021, we paid ColoAlert AS $27,335 and $0, respectively. On June 30, 2022 and December 31, 2021, we had liabilities recorded for unpaid costs to ColoAlert AS of $104,840 and $84,750, respectively, recorded as Accounts payable – related party.

Government Grants

Government Grants	6 Months Ended
	Jun. 30, 2022
Government Grants [Abstract]
GOVERNMENT GRANTS	14. GOVERNMENT GRANTS The Company receives government grants related to its research and development activities. The amount of government grants received during the periods ended June 30, 2022 and 2021 and recognized as research grant revenue were as follows: Six months ended June 30, Research and Development Projects 2022 2021 Rapid detection of antibody-based pathogens $ 19,072 $ 64,596 Multi-marker test for the early detection of pancreatic cancer 50,037 79,116 $ 69,109 $ 143,712 As of June 30, 2022 and December 31, 2021, the grants for rapid detection of antibody-based pathogens and a multi-marker test for the early detection of pancreatic cancer had remaining grant balances of approximately $168,161 and $254,796, respectively.

Financial Instrument Risk Manag

Financial Instrument Risk Management	6 Months Ended
	Jun. 30, 2022
Financial Instrument Risk Management [Abstract]
FINANCIAL INSTRUMENT RISK MANAGEMENT	15. FINANCIAL INSTRUMENT RISK MANAGEMENT Basis of Fair Value Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are: ● Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities; ● Level 2 — Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and ● Level 3 — Inputs that are not based on observable market data. The Company’s financial instruments consist of cash, trade and other receivables, accounts payable and accrued liabilities, lease liabilities, convertible debentures, and loans payable. With the exception of convertible debentures and loans payable, the carrying value of the Company’s financial instruments approximate their fair values due to their short-term maturities. The fair value of convertible debentures and notes payable approximate their carrying value, excluding discounts, due to minimal changes in interest rates and the Company’s credit risk since issuance of the instruments. The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. Credit Risk The Company’s principal financial assets are cash and trade receivables. The Company’s credit risk is primarily concentrated in its cash which is held with institutions with a high credit worthiness. The Company carries cash balances at US financial institutions more than the federally insured limit of $250,000 per institution and German €100,000 limit per institution. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. Management believes that the Company is not exposed to any significant credit risk with respect to its cash. The Company mitigates its credit risk on receivables by actively managing and monitoring its receivables. The Company has been determined that no credit loss provision is required, as all amounts outstanding are considered collectible. During the six months ended June 30, 2022, the Company incurred $470 in bad debt expense (2021 - $0). The Company mitigates credit risk by evaluating the creditworthiness of customers prior to conducting business with them and monitoring its exposure for credit losses with existing customers. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company’s normal operating requirements on an ongoing basis. As at June 30, 2022, the Company had an unrestricted cash balance of $26,006,609 to settle current liabilities of $2,473,562. Historically, the Company’s primary source of funding has been the issuance of equity securities for cash, primarily through the issuance of ordinary shares and credit facility borrowings. The Company’s access to financing is always uncertain. There can be no assurance of continued access to equity or debt financing. The following is an analysis of the contractual maturities of the Company’s financial liabilities as at June 30, 2022: Within Between one and More than one year five years five years Accounts payable and accrued liabilities $ 1,310,628 $ - $ - Accounts payable - related party 44,447 - - Convertible debt - related party 72,930 - - Silent partnerships 930,888 894,832 - Lease liabilities 114,669 375,494 99,654 $ 2,473,562 $ 1,270,326 $ 99,654 Foreign Exchange Risk Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which we also expect to be the currency of the Company’s largest cash outlays over the next twenty-four months. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to interest rate risk as its financial liabilities carry interest at fixed rates. Capital Management In the management of capital, the Company includes components of stockholders’ equity. The Company aims to manage its capital resources to ensure financial strength and to maximize its financial flexibility by maintaining strong liquidity and by utilizing alternative sources of capital including equity, debt and bank loans or lines of credit to fund continued growth. The Company sets the amount of capital in proportion to risk and based on the availability of funding sources. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. As a young growth company, issuance of equity has been the primary source of capital to date. Additional debt and/or equity financing may be pursued in future as deemed appropriate to balance debt and equity. To maintain or adjust the capital structure, the Company may issue new shares, take on additional debt or sell assets to reduce debt.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2022
Concentrations Disclosure Abstract
CONCENTRATIONS	16. CONCENTRATIONS Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the six months ended June 30, 2022 and 2021, the Company had revenue from four and two customers that accounted for approximately 81% and 51% of revenue, respectively.

Operating Expenses

Operating Expenses	6 Months Ended
	Jun. 30, 2022
Disclosure Of Operating Expenses [Abstract]
OPERATING EXPENSES	17. OPERATING EXPENSES For the years ended June 30, 2022 and 2021, operating expenses consisted of the follows, General and administrative 2022 2021 Bad Debt $ 470 $ - Consulting expenses 323,998 20,378 Depreciation and amortization 28,463 15,801 Office expenses 293,137 26,823 Professional fees 1,596,931 14,521 Salaries and benefits 1,968,706 172,192 Employee stock option expense 4,894,450 - Travel and entertainment 107,229 977 Royalty expenses 54,670 - $ 9,268,054 $ 250,692 Sales and marketing 2022 2021 Marketing and advertising $ 2,239,283 $ 80,798 Consulting expenses 97,346 6,123 Depreciation and amortization 8,551 4,748 Office expenses 43,860 6,930 Salaries and Benefits 131,456 51,736 $ 2,520,496 $ 150,335 Research and development 2022 2021 Consulting expenses $ 288,593 $ 18,151 Depreciation and amortization 25,353 14,074 Lab and office expenses 136,553 20,546 Salaries and benefits 389,714 153,375 Materials for clinical study 71,503 - $ 911,716 $ 206,146

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Inventories	Inventories Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on a weighted average cost and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current year presentation.
Critical Accounting Estimates and Significant Management Judgments	Critical Accounting Estimates and Significant Management Judgments The preparation of financial statements in accordance with IFRS requires the Company to use judgment in applying its accounting policies and make estimates and assumptions about reported amounts at the date of the financial statements and in the future. The Company’s management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Useful lives of property and equipment Estimates of the useful lives of property and equipment are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to physical wear and tear, technical or commercial obsolescence, not electing to exercise renewal options on Leases, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances. A reduction in the estimated useful lives of the property and equipment would increase the recorded expenses and decrease the non-current assets. Provision for expected credit losses on trade receivables The provision for expected credit losses on trade receivables are estimated based on historical information, customer concentrations, customer solvency, current economic and geographical trends, and changes in customer payment terms and practices. The Company will calibrate its provision matrix to adjust the historical credit loss experience with forward-looking information. The assessment of the correlation between historical observed default rates, forecast economic conditions and expected credit losses is a significant estimate. The amount of expected credit losses is sensitive to changes in circumstances and of forecast economic conditions. The Company’s historical credit loss experience and forecast of economic conditions may also not be representative of customer’s actual default in the future. Estimating the incremental borrowing rate on leases The Company cannot readily determine the interest rate implicit in leases where it is the lessee. As such, it uses its incremental borrowing rate (“IBR”) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of comparable value to the right-of-use asset in a similar economic environment. IBR therefore reflects what the Company “would have to pay”, which requires estimation when no observable rates are available or where the applicable rates need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates. Estimating the fair value of share-based payment transactions The Company utilizes a Black-Scholes model, or where appropriate, a Monte-Carlo Simulation to estimate the fair value of its share-based payments. In applying these models, management must estimate the expected future volatility of the Company’s estimated share price, and makes such assumptions based on a proxy of publicly-listed entities under an expectation that historical volatility is representative of the expected future volatility. Additionally, estimates have been made by management, in respect of the performance warrants, regarding the length of the vesting period as well as the number of performance warrants that are likely to vest. Estimating the fair value of financial instruments When the Company recognizes a financial instrument, where there is no active market for such instrument, the Company utilizes alternative valuation methods. The Company utilizes inputs from observable markets to the extent that an appropriate market can be identified, but when there is a lack of such a market, the Company applies judgment to determine a fair value. Such judgments require those such as risk and volatility, of which changes in such assumptions may impact the fair value of the financial instrument. Other significant judgments The preparation of these financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company’s financial statements include: ● The assessment of the Company’s ability to continue as a going concern and whether there are events or conditions that may give rise to significant uncertainty; ● The determination of the lease term of contracts with renewal and termination options; ● Determination of the extent to which it is probable that future taxable income will be available to allow all or part of the temporary differences and net operating losses to be utilized; ● Whether there are indicators of impairment of the Company’s long-lived assets; ● That Mainz Biomed N.V. did not constitute a business at the time of the contribution agreement; and ● Development costs do not meet the conditions for capitalization in accordance with IAS 38 and therefore all research and development costs have been expensed as incurred.

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2022
Trade and other receivables [Abstract]
Schedule of trade and other receivables	June 30, December 31, 2022 2021 Accounts receivable $ 59,768 $ 17,995 Less: allowance for doubtful accounts (734 ) (796 ) Accounts receivable, net 59,034 17,199 VAT receivable 271,694 94,085 Other 2,190 558 $ 332,918 $ 111,842

Prepaid and Other Current Ass_2

Prepaid and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Prepaid and Other Current Assets [Abstract]
Schedule of prepaid and other current assets	June 30, December 31, 2022 2021 Prepaid insurance $ 361,185 $ 743,750 Other prepaid expense 31,665 12,590 Security deposit 29,240 13,485 $ 422,090 $ 769,825

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Leases Text Block Abstract
Schedule of leases certain assets under lease agreements	Office Laboratory Equipment Equipment Vehicles Office lease Total Cost Balance at January 1, 2021 $ 31,584 $ 11,234 $ - $ 527,285 $ 570,103 Additions 20,233 12,121 - - 32,354 Effects of currency translation (3,063 ) (1,279 ) - (38,142 ) (42,484 ) Balance at December 31, 2021 $ 48,754 $ 22,076 $ - $ 489,143 $ 559,973 Additions 18,610 117,011 58,834 40,768 235,223 Effects of currency translation (4,593 ) (6,549 ) (2,422 ) (40,067 ) (53,631 ) Balance at June 30, 2022 $ 62,771 $ 132,538 $ 56,412 $ 489,844 $ 741,565 Accumulated amortization Balance at January 1, 2021 $ 3,983 $ 2,340 $ - $ 107,245 $ 113,568 Amortization 6,135 5,487 - 51,734 63,356 Effects of currency translation (524 ) (380 ) - (9,749 ) (10,653 ) Balance at December 31, 2021 $ 9,594 $ 7,447 $ - $ 149,230 $ 166,271 Amortization 5,788 14,143 7,080 25,943 52,954 Effects of currency translation (991 ) (1,166 ) (291 ) (12,781 ) (15,229 ) Balance at June 30, 2022 $ 14,391 $ 20,424 $ 6,789 $ 162,392 $ 203,996
Schedule of future lease payments	Total Balance as of January 1, 2021 $ 495,051 Additions 32,955 Interest expenses 47,102 Lease payments (97,429 ) Effects of currency translation (34,835 ) As of December 31, 2021 $ 442,844 Additions 235,221 Interest expenses 25,338 Lease payments (71,029 ) Effects of currency translation (42,557 ) As of June 30, 2022 $ 589,817
Schedule of lease liabilities	Lease liabilities June 30, December 31, Current portion $ 114,669 $ 55,076 Long-term portion 475,148 387,766 Total lease liabilities $ 589,817 $ 442,842
Schedule of committed to minimum lease payments	Maturity analysis June 30, Less than one year $ 77,108 One to two years 154,216 Two to three years 151,782 Three to four years 95,580 Four to five years 82,443 More than five years 133,238 Total undiscounted lease liabilities $ 694,367 Amount representing implicit interest (104,550 ) Lease obligations $ 589,817

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Accounts Payable And Accrued Expenses Abstract
Schedule of accounts payable and accrued expenses	June 30, December 31, 2022 2021 Accounts payable $ 503,181 $ 747,768 Accrued liabilities 51,633 26,989 Payroll liabilities 50,974 6,812 Bonus accrual 600,000 - VAT payable - 3,217 $ 1,205,788 $ 784,786

Convertible Debt _ Related Pa_2

Convertible Debt – Related Party (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Convertible Debt Explanatory Abstract
Schedule of convertible debt	2019 and 2020 2017 Total Balance, January 1, 2021 $ 447,181 $ 86,189 $ 533,370 Accretion 60,136 - 60,136 Conversion (471,528 ) (36,709 ) (508,237 ) Effects of currency translation (3,568 ) (3,814 ) (7,382 ) Balance, December 31, 2021 $ 32,221 $ 45,666 $ 77,887 Accretion 1,205 - 1,205 Effects of currency translation (2,578 ) (3,584 ) (6,162 ) Balance, June 30, 2022 $ 30,848 $ 42,082 $ 72,930

Loans Payable (Tables)

Loans Payable (Tables)	6 Months Ended
	Jun. 30, 2022
Loans Payable [Abstract]
Schedule of loans payable	0.1% Loan Related party Related party Total Balance, January 1, 2021 $ 24,528 $ 41,326 $ 66,979 $ 132,833 Issued during the year - - 2,305 2,305 Extinguished during the year - - (11,832 ) (11,832 ) Accretion - 1,542 - 1,542 Effects of currency translation (1,774 ) (3,049 ) (4,479 ) (9,302 ) Balance, December 31, 2021 $ 22,754 $ 39,819 $ 52,973 $ 115,546 Extinguished during the year (21,868 ) (38,269 ) (52,777 ) (112,914 ) Effects of currency translation (886 ) (1,550 ) (196 ) (2,632 ) Balance, June 30, 2022 $ - $ - $ - $ -

Silent Partnerships (Tables)

Silent Partnerships (Tables)	6 Months Ended
	Jun. 30, 2022
Silent Partnerships Abstract
Schedule of continuity of the company’s silent partnerships	3% SPAs 3.5% SPAs 8.5% SPAs 8% SPAs Total Balance, January 1, 2021 $ 288,558 $ 43,313 $ 1,030,167 $ 456,212 $ 1,818,250 Issued during the year 236,636 - - - 236,636 Discount - - (51,410 ) - (51,410 ) Accretion 34,970 3,214 30,018 10,093 78,295 Effects of currency translation (31,315 ) (3,256 ) (73,694 ) (33,387 ) (141,652 ) Balance, December 31, 2021 $ 528,849 $ 43,271 $ 935,081 $ 432,918 $ 1,940,119 Accretion 19,166 1,557 14,066 4,704 39,493 Effects of currency translation (42,294 ) (3,460 ) (73,967 ) (34,171 ) (153,892 ) Balance, June 30, 2022 $ 505,721 $ 41,368 $ 875,180 $ 403,451 $ 1,825,720

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of the estimated fair values of the warrants measured	December 31, 2021 Stock price at time of issuance $ 0.283 - 1.602 Exercise price $ 3.00 Expected term 2 - 5 years Expected average volatility 75 - 95 % Expected dividend yield 0 Risk-free interest rate 0.16 - 1.08 % June 30, 2022 Exercise price $ 8.91 - 20.87 Expected term 5.55 - 6.75 years Expected average volatility 73% - 79 % Expected dividend yield - Risk-free interest rate 1.26% - 3.38 %
Schedule of activity during the year ended	Warrants Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2021 3,895,000 $ 3.08 1.60 Grants - - - Exercised (507,500 ) 3.00 1.46 Expired - - - Balance as of June 30, 2022 3,387,500 $ 3.08 1.08 Stock Options Weighted-Average Weighted-Average Outstanding Exercise Price Life (years) Balance as of December 31, 2021 1,504,650 $ 5.10 9.85 Grants 487,000 13.16 10.00 Exercised - - - Expiry - - - Balance as of June 30, 2022 1,991,650 $ 7.07 9.46 Exercisable as of June 30, 2022 933,040 $ 5.14 9.36

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Schedule of remuneration of directors and key management personnel	Six months ended June 30, 2022 2021 Salaries and benefits $ 1,264,187 $ 109,733
Schedule of remuneration paid to related parties	Six months ended June 30, 2022 2021 Salaries and benefits $ 61,116 $ 943

Government Grants (Tables)

Government Grants (Tables)	6 Months Ended
	Jun. 30, 2022
Government Grants [Abstract]
Schedule of research and development	Six months ended June 30, Research and Development Projects 2022 2021 Rapid detection of antibody-based pathogens $ 19,072 $ 64,596 Multi-marker test for the early detection of pancreatic cancer 50,037 79,116 $ 69,109 $ 143,712

Financial Instrument Risk Man_2

Financial Instrument Risk Management (Tables)	6 Months Ended
	Jun. 30, 2022
Financial Instrument Risk Management [Abstract]
Schedule of contractual maturities financial liabilities	Within Between one and More than one year five years five years Accounts payable and accrued liabilities $ 1,310,628 $ - $ - Accounts payable - related party 44,447 - - Convertible debt - related party 72,930 - - Silent partnerships 930,888 894,832 - Lease liabilities 114,669 375,494 99,654 $ 2,473,562 $ 1,270,326 $ 99,654

Operating Expenses (Tables)

Operating Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Operating Expenses [Abstract]
Schedule of operating expenses	General and administrative 2022 2021 Bad Debt $ 470 $ - Consulting expenses 323,998 20,378 Depreciation and amortization 28,463 15,801 Office expenses 293,137 26,823 Professional fees 1,596,931 14,521 Salaries and benefits 1,968,706 172,192 Employee stock option expense 4,894,450 - Travel and entertainment 107,229 977 Royalty expenses 54,670 - $ 9,268,054 $ 250,692 Sales and marketing 2022 2021 Marketing and advertising $ 2,239,283 $ 80,798 Consulting expenses 97,346 6,123 Depreciation and amortization 8,551 4,748 Office expenses 43,860 6,930 Salaries and Benefits 131,456 51,736 $ 2,520,496 $ 150,335 Research and development 2022 2021 Consulting expenses $ 288,593 $ 18,151 Depreciation and amortization 25,353 14,074 Lab and office expenses 136,553 20,546 Salaries and benefits 389,714 153,375 Materials for clinical study 71,503 - $ 911,716 $ 206,146

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) - USD ($)		1 Months Ended	6 Months Ended
	Aug. 03, 2021	Nov. 30, 2021	Jun. 30, 2022
Nature of Operations and Going Concern [Abstract]
Agreement percentage	100%
Share exchange	6,000,000
Outstanding shares percentage	62%
Shares sold		2,300,000
Shares per share		$ 5
Accumulated deficit total			$ 29,247,405
Operating activities			$ 6,456,904

Trade and Other Receivables (De

Trade and Other Receivables (Details) - Schedule of trade and other receivables - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Trade And Other Receivables Abstract
Accounts receivable	$ 59,768	$ 17,995
Less: allowance for doubtful accounts	(734)	(796)
Accounts receivable, net	59,034	17,199
VAT receivable	271,694	94,085
Other	2,190	558
Total	$ 332,918	$ 111,842

Prepaid and Other Current Ass_3

Prepaid and Other Current Assets (Details) - Schedule of prepaid and other current assets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Prepaid And Other Current Assets Abstract
Prepaid insurance	$ 361,185	$ 743,750
Other prepaid expense	31,665	12,590
Security deposit	29,240	13,485
Total prepaid and other current assets	$ 422,090	$ 769,825

Leases (Details)

Leases (Details)			6 Months Ended
	Jan. 01, 2021	Jan. 01, 2020	Jun. 30, 2022
Disclosure Of Leases Text Block Abstract
Average expected life			5 years
Present value of future lease payments percentage	10%	10%

Leases (Details) - Schedule of

Leases (Details) - Schedule of leases certain assets under lease agreements - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Cost
Balance	$ 559,973	$ 570,103
Additions	235,223	32,354
Effects of currency translation	(53,631)	(42,484)
Balance	741,565	559,973
Accumulated amortization
Balance	166,271	113,568
Amortization	52,954	63,356
Effects of currency translation	(15,229)	(10,653)
Balance	203,996	166,271
Office Equipment [Member]
Cost
Balance	48,754	31,584
Additions	18,610	20,233
Effects of currency translation	(4,593)	(3,063)
Balance	62,771	48,754
Accumulated amortization
Balance	9,594	3,983
Amortization	5,788	6,135
Effects of currency translation	(991)	(524)
Balance	14,391	9,594
Laboratory Equipment [Member]
Cost
Balance	22,076	11,234
Additions	117,011	12,121
Effects of currency translation	(6,549)	(1,279)
Balance	132,538	22,076
Accumulated amortization
Balance	7,447	2,340
Amortization	14,143	5,487
Effects of currency translation	(1,166)	(380)
Balance	20,424	7,447
Vehicles [Member]
Cost
Balance
Additions	58,834
Effects of currency translation	(2,422)
Balance	56,412
Accumulated amortization
Balance
Amortization	7,080
Effects of currency translation	(291)
Balance	6,789
Office lease [Member]
Cost
Balance	489,143	527,285
Additions	40,768
Effects of currency translation	(40,067)	(38,142)
Balance	489,844	489,143
Accumulated amortization
Balance	149,230	107,245
Amortization	25,943	51,734
Effects of currency translation	(12,781)	(9,749)
Balance	$ 162,392	$ 149,230

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of future lease payments - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Future Lease Payments Abstract
Balance at beginning	$ 442,844	$ 495,051
Additions	235,221	32,955
Interest expenses	25,338	47,102
Lease payments	(71,029)	(97,429)
Effects of currency translation	(42,557)	(34,835)
Balance at ending	$ 589,817	$ 442,844

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease liabilities - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Lease Liabilities Abstract
Current portion	$ 114,669	$ 55,076
Long-term portion	475,148	387,766
Total lease liabilities	$ 589,817	$ 442,842

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of committed to minimum lease payments	6 Months Ended
	Jun. 30, 2022 USD ($)
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	$ 694,367
Amount representing implicit interest	(104,550)
Lease obligations	589,817
Less than one year [Member]
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	77,108
One to two years [Member]
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	154,216
Two to three years [Member]
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	151,782
Three to four years [Member]
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	95,580
Four to five years [Member]
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	82,443
More than five years [Member]
Leases (Details) - Schedule of committed to minimum lease payments [Line Items]
Total undiscounted lease liabilities	$ 133,238

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - Schedule of accounts payable and accrued expenses - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Accounts Payable And Accrued Expenses Abstract
Accounts payable	$ 503,181	$ 747,768
Accrued liabilities	51,633	26,989
Payroll liabilities	50,974	6,812
Bonus accrual	600,000
VAT payable		3,217
Total	$ 1,205,788	$ 784,786

Convertible Debt _ Related Pa_3

Convertible Debt – Related Party (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 € / shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)	Nov. 30, 2017
Disclosure Of Convertible Debt Explanatory Abstract
Loan agreements totalling				$ 467,154	€ 417,133	$ 467,154	€ 417,133
Bear interest	3.50%
Loans outstanding, percentage	0.50%
Per share (in Euro per share) | € / shares	€ 1
Debt discount totalling | €					€ 13,064		€ 13,064
Loan agreements, description								the Company entered into loan agreements with two shareholders of the Company for loans totaling EUR 80,278 (approximately $92,007) (the “2017 Convertible Loans”). The loans are convertible at the option of the lender to shares totaling 4.25% of the Company’s common shares outstanding at the time of conversion. The loans are non-interest bearing, are unsecured and are due on demand. During the year ended December 31, 2019, principal in the amount of EUR 5,000 ($5,597) was exchanged for the 2019 and 2020 Convertible Loans and EUR 5,000 ($5,597) was extinguished as the lender elected to offset the debt amount against amounts in trade receivables due to the Company.
Loan amount		$ (508,237)	€ 417,272
Converted share capital (in Shares) | shares		392,757	392,757
Cash received		$ (7,673)	€ 6,485

Convertible Debt _ Related Pa_4

Convertible Debt – Related Party (Details) - Schedule of convertible debt - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Convertible Debt – Related Party (Details) - Schedule of convertible debt [Line Items]
Beginning balance	$ 77,887	$ 533,370
Accretion	1,205	60,136
Conversion		(508,237)
Effects of currency translation	(6,162)	(7,382)
Ending balance	72,930	77,887
2019 and 2020 Convertible Loans [Member]
Convertible Debt – Related Party (Details) - Schedule of convertible debt [Line Items]
Beginning balance	32,221	447,181
Accretion	1,205	60,136
Conversion		(471,528)
Effects of currency translation	(2,578)	(3,568)
Ending balance	30,848	32,221
2017 Convertible Loans [Member]
Convertible Debt – Related Party (Details) - Schedule of convertible debt [Line Items]
Beginning balance	45,666	86,189
Accretion
Conversion		(36,709)
Effects of currency translation	(3,584)	(3,814)
Ending balance	$ 42,082	$ 45,666

Loans Payable (Details)

Loans Payable (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Jun. 30, 2022 EUR (€)
Loans Payable [Abstract]
Principal amount		$ 22,828	€ 20,000
Loan amount in percentage		0.10%	0.10%
Loan bears interest		0.10%	0.10%
Trade receivables percentage		0.10%	0.10%
Received loans from related parties	$ 40,144					€ 35,000
Related party loans percentage	6%
Loans payable description	The Loans have a stated interest rate of at 6.0%. EUR 10,000 (approximately $11,461) of the loans matured on July 31, 2020 and EUR 25,000 (approximately $28,653) of the loan matured on December 31, 2021. As the Related Party 6% Loans were received at below market interest rates, the initial fair value of the 3% Loan was determined to be EUR 21,936 (approximately $25,140), determined using an estimated effective interest rate of 11.5%.
Line of credit				$ 229,224	€ 200,000
Accrues interest				4%	4%
Line of control				0.50%	0.50%

Loans Payable (Details) - Sched

Loans Payable (Details) - Schedule of loans payable - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Loans Payable (Details) - Schedule of loans payable [Line Items]
Opening Balance		$ 132,833
Issued during the year		2,305
Extinguished during the year	$ (112,914)	(11,832)
Accretion		1,542
Effects of currency translation	(2,632)	(9,302)
Ending Balance		115,546
0.1% Loan [Member]
Loans Payable (Details) - Schedule of loans payable [Line Items]
Opening Balance		24,528
Issued during the year
Extinguished during the year	(21,868)
Accretion
Effects of currency translation	(886)	(1,774)
Ending Balance		22,754
6% Loans [Member]
Loans Payable (Details) - Schedule of loans payable [Line Items]
Opening Balance		41,326
Issued during the year
Extinguished during the year	(38,269)
Accretion		1,542
Effects of currency translation	(1,550)	(3,049)
Ending Balance		39,819
LOC [Member]
Loans Payable (Details) - Schedule of loans payable [Line Items]
Opening Balance		66,979
Issued during the year		2,305
Extinguished during the year	(52,777)	(11,832)
Accretion
Effects of currency translation	(196)	(4,479)
Ending Balance		$ 52,973

Silent Partnerships (Details)

Silent Partnerships (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€) € / shares	Dec. 31, 2010 USD ($)	Dec. 31, 2010 EUR (€)
Silent Partnerships (Details) [Line Items]
Silent partnership agreements description	the Company entered into silent partnership agreements whereby the lender agreed to lend a total of EUR 299,400 (approximately $341,740) (the “3% SPAs”). The Company is to repay the amount by December 31, 2025. The Company must pay a minimum of 3% interest per annum on the loans. The lender is entitled to 3% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lender does not partake in the Company’s losses. Upon the amounts coming due, the lender of the 3% SPAs have the option to demand an additional payment equal to 15% of the contribution as a final remuneration (the “Final Renumeration”). The Final Remuneration is considered to be the cost of issuing debt. The 3% SPAs were received at below market interest rates as part of a government program for COVID-19 relief. The initial fair value of the 3% SPAs was determined to be EUR 218,120 (approximately $248,966), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3% SPAs of EUR 81,280 ($92,774) has been recognized as government grant income during the period. During the year ended December 31, 2021 the Company received the remaining EUR 200,000 ($236,640). The initial fair value of the 3.0% SPAs received was determined to be EUR 230,000 (approximately $272,136), determined using an estimated effective interest rate of 11.5%. The initial fair value of the 3.0% SPAs received in 2021 was determined to be EUR 156,549 (approximately $185,229), which was determined using an estimated effective interest rate of 11.5%. The difference between the face value and the fair value of the 3.0% SPAs received in 2021 of EUR 43,451 (approximately $51,410) has been recognized as government grant income during the period
Agreed to lend a total		$ 57,071	€ 50,000	$ 343,830	€ 300,000
Convertible to common shares percentage			3.50%	8%	8%
Amount repayment date		Jun. 30, 2025	Jun. 30, 2025	Jan. 31, 2023	Jan. 31, 2023
Interest rate per annum			3.50%	8%	8%
Net income percent			0.50%
Per share (in Euro per share)			€ 1
Principal amount percentage			3.50%
Net income percent				1.95%	1.95%
Additional payment percentage				30%	30%
Initial fair value rate				8%	8%
Initial fair value amount				$ 332,254	€ 289,900
SPAs [Member]
Silent Partnerships (Details) [Line Items]
Silent partnership agreements description	Between the years of 2013 to 2016, the Company entered into silent partnership agreements for loans totaling EUR 798,694 (approximately $915,383) (the “8.5% SPAs”). Under the 8.5% SPAs, the Company is to repay EUR 398,634 (approximately $408,496) of the loans by June 30, 2023 and EUR 400,000 (approximately $409,859) of the loans matures on December 31, 2025. The Company must pay a minimum of 8.5% interest per annum on the loans. The lenders are entitled to 1.66% of the Company’s net income each year should the Company be profitable and provided that the amount paid does not exceed the principal amount of the debt; the lenders do not partake in the Company’s losses. At maturity, the lenders of the 8.5% SPAs have the option to demand an additional payment equal to 30% of the principal of the loans as a Final Remuneration. The Final Remuneration is considered to be cost of issuing the debt and as such, the initial fair value of the 8.5% SPAs was determined to be EUR 772,568 (approximately $85,440), determined using an estimated effective interest rate of 11.5%. Under the agreements, the lenders also agreed to invest in the Company and contributed EUR 676,366 (approximately $775,183) to acquire 27,752 shares of the Company between the years of 2013 and 2016. During the year ended December 31, 2020, EUR 80,000 (approximately $99,527) of the 8.5% SPAs was extinguished as the lender, who is also a customer of the Company, elected to offset the debt amount against amounts in trade receivables due to the Company. The debtor did not demand the Final Remuneration and the Company recognized a gain on the extinguishment of $8,214.
Convertible to common shares percentage			3.50%	8%	8%
Interest rate per annum			3.50%	11.50%	11.50%

Silent Partnerships (Details) -

Silent Partnerships (Details) - Schedule of continuity of the company’s silent partnerships - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Silent Partnerships (Details) - Schedule of continuity of the company’s silent partnerships [Line Items]
Balance beginning	$ 1,940,119	$ 1,818,250
Balance ending	1,825,720	1,940,119
Extinguished during the year		236,636
Discount		(51,410)
Accretion	39,493	78,295
Effects of currency translation	(153,892)	(141,652)
3% SPAs [Member]
Silent Partnerships (Details) - Schedule of continuity of the company’s silent partnerships [Line Items]
Balance beginning	528,849	288,558
Balance ending	505,721	528,849
Extinguished during the year		236,636
Discount
Accretion	19,166	34,970
Effects of currency translation	(42,294)	(31,315)
3.5% SPAs [Member]
Silent Partnerships (Details) - Schedule of continuity of the company’s silent partnerships [Line Items]
Balance beginning	43,271	43,313
Balance ending	41,368	43,271
Extinguished during the year
Discount
Accretion	1,557	3,214
Effects of currency translation	(3,460)	(3,256)
8.5% SPAs [Member]
Silent Partnerships (Details) - Schedule of continuity of the company’s silent partnerships [Line Items]
Balance beginning	935,081	1,030,167
Balance ending	875,180	935,081
Extinguished during the year
Discount		(51,410)
Accretion	14,066	30,018
Effects of currency translation	(73,967)	(73,694)
8% SPAs [Member]
Silent Partnerships (Details) - Schedule of continuity of the company’s silent partnerships [Line Items]
Balance beginning	432,918	456,212
Balance ending	403,451	432,918
Extinguished during the year
Discount
Accretion	4,704	10,093
Effects of currency translation	$ (34,171)	$ (33,387)

Equity (Details)

Equity (Details)	6 Months Ended			12 Months Ended
	Jun. 30, 2022 USD ($) shares	Jun. 30, 2022 € / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Equity (Details) [Line Items]
Ordinary shares authorized (in Shares) | shares	45,000,000	45,000,000
Voting rights, description	Holders of ordinary shares are entitled to dividends as declared from time to time and are entitled to one vote per share at general meetings of the Company.
Share capital per share. (in Euro per share) | € / shares		€ 0.01
Initial public offering shares (in Shares) | shares	1,725,000	1,725,000
Gross proceeds	$ 25.9
Aggregate proceeds	$ 23.9
Ordinary shares (in Shares) | shares	689,973	689,973
Proceeds from exercise of warrants	$ 382,500
Conversion of debt (in Shares) | shares	58,000
Net of fees and expenses	$ 787,620
Warrants issued (in Shares) | shares	3,755,000
Underwriting warrants (in Shares) | shares	140,000
Underwriting warrant in amount	$ 754,286
Granted shares (in Shares) | shares	487,000			1,504,650
Stock options				$ 13,968,627
Share-based compensation	$ 4,894,450			6,430,158
Unamortized expense				$ 7,538,469
Stock option of granted value	4,336,798
Unamortized expense	$ 6,952,548
Stock Option [Member]
Equity (Details) [Line Items]
Ordinary shares (in Shares) | shares				2,800,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of estimated fair values of the warrants measured - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Warrants [Member]
Equity (Details) - Schedule of estimated fair values of the warrants measured [Line Items]
Exercise price (in Dollars per share)		$ 3
Warrants [Member] | Minimum [Member]
Equity (Details) - Schedule of estimated fair values of the warrants measured [Line Items]
Stock price at time of issuance (in Dollars per share)		$ 0.283
Expected term		2 years
Expected average volatility		75%
Risk-free interest rate		0.16%
Warrants [Member] | Maximum [Member]
Equity (Details) - Schedule of estimated fair values of the warrants measured [Line Items]
Stock price at time of issuance (in Dollars per share)		$ 1.602
Expected term		5 years
Expected average volatility		95%
Risk-free interest rate		1.08%
Stock options [Member]
Equity (Details) - Schedule of estimated fair values of the warrants measured [Line Items]
Expected dividend yield (in Dollars)		$ 0
Stock options [Member] | Minimum [Member]
Equity (Details) - Schedule of estimated fair values of the warrants measured [Line Items]
Exercise price (in Dollars per share)	$ 8.91
Expected term	5 years 6 months 18 days
Expected average volatility	73%
Risk-free interest rate	1.26%
Stock options [Member] | Maximum [Member]
Equity (Details) - Schedule of estimated fair values of the warrants measured [Line Items]
Exercise price (in Dollars per share)	$ 20.87
Expected term	6 years 9 months
Expected average volatility	79%
Risk-free interest rate	3.38%

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of activity during the year ended - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Equity (Details) - Schedule of activity during the year ended [Line Items]
Outstanding, Beginning Balance	3,895,000
Weighted-Average Exercise Price, Beginning Balance	$ 3.08
Weighted-Average Life (years), Beginning Balance	1 year 7 months 6 days
Outstanding, Grants
Weighted-Average Exercise Price, Grants
Weighted-Average Life (years), Grants
Outstanding, Exercised
Weighted-Average Exercise Price, Exercised
Weighted-Average Life (years), Exercised
Outstanding, Expired
Weighted-Average Exercise Price, Expired
Weighted-Average Life (years), Expired
Outstanding, Ending Balance	3,387,500	1,991,650	3,895,000
Weighted-Average Exercise Price, Ending Balance	$ 3.08	$ 7.07	$ 3.08
Weighted-Average Life (years), Ending Balance	1 year 29 days	9 years 5 months 15 days
Outstanding, Exercisable		933,040
Weighted-Average Exercise Price, Exercisable		$ 5.14
Weighted-Average Life (years), Exercisable		9 years 4 months 9 days
Stock Option [Member]
Equity (Details) - Schedule of activity during the year ended [Line Items]
Outstanding, Beginning Balance		1,504,650	1,504,650
Weighted-Average Exercise Price, Beginning Balance		$ 5.1	$ 5.1
Weighted-Average Life (years), Beginning Balance		9 years 10 months 6 days
Outstanding, Grants		487,000
Weighted-Average Exercise Price, Grants		$ 13.16
Weighted-Average Life (years), Grants		10 years
Outstanding, Exercised	(507,500)
Weighted-Average Exercise Price, Exercised	$ 3
Weighted-Average Life (years), Exercised	1 year 5 months 15 days
Outstanding, Expired
Weighted-Average Exercise Price, Expired
Weighted-Average Life (years), Expired

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Related Party Transactions [Abstract]
Incurred interest expense	$ 16,838	$ 24,983
Incurred accretion expense	$ 7,885	$ 9,908
Related party balances description	As at June 30, 2022, EUR 30,000 (approximately $31,452) with a carrying value of $30,848 (2021 – $33,767) of the 2019 and 2020 Convertible Loans were owing to the Chief Scientific Officer of the Company and a major shareholder of the Company, respectively. The amounts are due on September 30, 2022. As at June 30, 2022, EUR 350,000 (approximately $366,940) (2021 – EUR 350,000) with a carrying value of $445,174 (2021 – $498,972) of the 8.5% SPAs were owing to major shareholders of the Company. EUR 150,000 of the loan is due on June 30, 2023 and EUR 200,000 of the loan is due on December 31, 2025. During the six months ended June 30, 2022 and 2021, we recorded expenses of $126,173 and $0, respectively, for the cost of royalties and other associated costs owed to ColoAlert AS, the company from which we exclusively license the ColoAlert product. Our Board Chairman is also a significant equity holder of ColoAlert AS. During the six months ended June 30, 2022 and 2021, we paid ColoAlert AS $27,335 and $0, respectively. On June 30, 2022 and December 31, 2021, we had liabilities recorded for unpaid costs to ColoAlert AS of $104,840 and $84,750, respectively, recorded as Accounts payable – related party.

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of remuneration of directors and key management personnel - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Remuneration Of Directors And Key Management Personnel Abstract
Salaries and benefits	$ 1,264,187	$ 109,733

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of remuneration paid to related parties - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Remuneration Paid To Related Parties Abstract
Salaries and benefits	$ 61,116	$ 943

Government Grants (Details)

Government Grants (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Government Grants [Abstract]
Multi-marker test	$ 168,161
Antibody-based pathogens		$ 254,796

Government Grants (Details) - S

Government Grants (Details) - Schedule of research and development - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Schedule Of Research And Development Abstract
Rapid detection of antibody-based pathogens	$ 19,072	$ 64,596
Multi-marker test for the early detection of pancreatic cancer	50,037	79,116
Total research and development projects	$ 69,109	$ 143,712

Financial Instrument Risk Man_3

Financial Instrument Risk Management (Details)	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 USD ($)
Financial Instrument Risk Management [Abstract]
Federal insured limit	$ 250,000	€ 100,000
Bad debt expense	470		$ 0
Unrestricted cash	26,006,609
Current liabilities	$ 2,473,562
Foreign exchange risk description	As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which we also expect to be the currency of the Company’s largest cash outlays over the next twenty-four months.	As the Company operates in Germany it holds a portion of its cash balances in Euro to approximate between three to twelve months estimated operating needs. The remainder of the Company’s cash is held in U.S. Dollars, the Company’s reporting currency, which we also expect to be the currency of the Company’s largest cash outlays over the next twenty-four months.

Financial Instrument Risk Man_4

Financial Instrument Risk Management (Details) - Schedule of contractual maturities financial liabilities	6 Months Ended
	Jun. 30, 2022 USD ($)
Within one year [Member]
Financial Instrument Risk Management (Details) - Schedule of contractual maturities financial liabilities [Line Items]
Accounts payable and accrued liabilities	$ 1,310,628
Accounts payable - related party	44,447
Convertible debt - related party	72,930
Silent partnerships	930,888
Lease liabilities	114,669
Total	2,473,562
Between one and five years [Member]
Financial Instrument Risk Management (Details) - Schedule of contractual maturities financial liabilities [Line Items]
Accounts payable and accrued liabilities
Accounts payable - related party
Convertible debt - related party
Silent partnerships	894,832
Lease liabilities	375,494
Total	1,270,326
More than five years [Member]
Financial Instrument Risk Management (Details) - Schedule of contractual maturities financial liabilities [Line Items]
Accounts payable and accrued liabilities
Accounts payable - related party
Convertible debt - related party
Silent partnerships
Lease liabilities	99,654
Total	$ 99,654

Concentrations (Details)

Concentrations (Details)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Concentrations Disclosure Abstract
Annual revenues percentage	10%
Number of customers	4	2
Revenue percentage	81%	51%

Operating Expenses (Details) -

Operating Expenses (Details) - Schedule of operating expenses - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
General and Administrative [Member]
Operating Expenses (Details) - Schedule of operating expenses [Line Items]
Bad Debt	$ 470
Consulting expenses	323,998	20,378
Depreciation and amortization	28,463	15,801
Office expenses	293,137	26,823
Professional fees	1,596,931	14,521
Salaries and benefits	1,968,706	172,192
Employee stock option expense	4,894,450
Travel and entertainment	107,229	977
Royalty expenses	54,670
General and administrative total	9,268,054	250,692
Sales and Marketing [Member]
Operating Expenses (Details) - Schedule of operating expenses [Line Items]
Marketing and advertising	2,239,283	80,798
Consulting expenses	97,346	6,123
Depreciation and amortization	8,551	4,748
Office expenses	43,860	6,930
Salaries and Benefits	131,456	51,736
Sales and marketing total	2,520,496	150,335
Research and Development [Member]
Operating Expenses (Details) - Schedule of operating expenses [Line Items]
Consulting expenses	288,593	18,151
Depreciation and amortization	25,353	14,074
Lab and office expenses	136,553	20,546
Salaries and benefits	389,714	153,375
Materials for clinical study	71,503
Research and development total	$ 911,716	$ 206,146